Trinity Capital Inc. Provides $15 Million in Growth Capital to Cagent Vascular Inc.

Whats Happening:

Trinity Capital Inc., a leading alternative asset manager, has committed $15 million in growth capital to Cagent Vascular Inc., a medical device company developing innovative vascular treatment technologies. This investment complements a $45 million equity financing round led by US Venture Partners in 2024, supporting Cagent Vascular's expansion and commercialization efforts for its Serranator product.

Key Moves:

• Trinity Capital commits $15 million in growth capital to Cagent Vascular

• Cagent Vascular received $45 million in equity financing led by US Venture Partners in 2024

• Funding supports commercialization of Cagent Vascular's Serranator product

By The Numbers:

• $15 million committed by Trinity Capital to Cagent Vascular

• $45 million equity financing led by US Venture Partners in 2024

• Over 20,000 procedures performed using Cagent Vascular's Serration technology

Key Quotes:

• "We are excited to partner with Cagent Vascular as they continue to innovate and expand their platform of valuable solutions for physicians treating patients with peripheral artery disease," - Ryan Kaeding, Managing Director, Life Sciences at Trinity Capital

• "Trinity Capital's support is appreciated as we build a leading vascular company and make a difference in the lives of patients around the globe." - Brian Walsh, Chairman and CEO of Cagent Vascular

Bottom Line:

Trinity Capital's $15 million investment in Cagent Vascular demonstrates confidence in the company's innovative vascular treatment technologies. This funding, combined with previous equity financing, positions Cagent Vascular to accelerate commercialization efforts and expand its impact in treating peripheral artery disease, potentially improving outcomes for patients worldwide.

Read Full Article